Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.01M-10.4% | -$62.53M-459% | -$11.18M+69.5% | -$36.72M+18.0% | -$44.77M+20.5% | ||
| $12.81M+30.5% | $9.81M+2.6% | $9.57M+2.0% | $9.38M+5.9% | $8.86M-3.9% | ||
| $30M+400% | -$10M— | $0-100% | $10M— | $0— | ||
| -$3.21M-322% | $1.45M-61.4% | $3.75M+16,183% | $23K-99.2% | $3.02M+167% | ||
| $3.65M— | —— | —— | -$2.3M+61.6% | -$6M-140% | ||
| $233K-91.9% | $2.88M-53.2% | $6.16M+45.0% | $4.25M+1,019% | -$462K— | ||
| $36K+101% | -$3.96M-200% | $3.94M+256% | -$2.52M-229% | $1.95M+331% | ||
| -$57.37M-28.7% | -$44.58M-20.1% | -$37.12M+20.3% | -$46.56M-13.6% | -$40.99M-10.2% | ||
| $81.17M-76.2% | $341.71M+361% | $74.19M+113% | $34.87M-51.2% | $71.44M-69.3% | ||
| $107.75M+14.3% | $94.3M-4.9% | $99.19M-7.2% | $106.87M+49.7% | $71.38M+14.1% | ||
| $30M— | —— | —— | $7M— | $0— | ||
| $56.58M+123% | -$247.41M-1,090% | $25M-68.4% | $79M+129,605% | -$61K+100.0% | ||
| $2.68M+53.0% | $1.75M+256% | $491K-42.1% | $848K+289% | $218K— | ||
| $12.26M-96.1% | $312.81M+6,837% | -$4.64M-735% | $731K+485% | $125K-99.9% | ||
| $11.46M— | —— | -$16.76M— | —— | -$40.93M— | ||
| $2.06M-1.2% | $2.09M+54.4% | $1.35M-32.9% | $2.01M-23.8% | $2.64M+9.2% | ||
| $0— | —— | —— | —— | $0— | ||
| -$30.27M— | —— | $40.4M— | —— | $2.4M— | ||
| -$3.21M-322% | $1.45M-61.4% | $3.75M+16,183% | $23K-99.2% | $3.02M+167% | ||
| $3.65M— | —— | —— | -$2.3M+61.6% | -$6M-140% | ||
| $36K+101% | -$3.96M-200% | $3.94M+256% | -$2.52M-229% | $1.95M+331% | ||
| $233K-91.9% | $2.88M-53.2% | $6.16M+45.0% | $4.25M+1,019% | -$462K— | ||
| $372K+510% | $61K-80.3% | $309K-74.9% | $1.23M+132% | $530K-24.5% | ||
| $107.75M+14.3% | $94.3M-4.9% | $99.19M-7.2% | $106.87M+49.7% | $71.38M+14.1% | ||
| $171K+148% | $69K— | —— | —— | $93K-71.7% | ||
| $9.75M-33.9% | $14.75M— | —— | —— | $0-100% | ||
| —— | $74.1M0.0% | $74.1M0.0% | $74.1M0.0% | $74.1M+37.3% | ||
| $2.68M+53.0% | $1.75M+256% | $491K-42.1% | $848K+289% | $218K-83.3% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $3K-97.2% | $107K— | —— | —— | $0-100% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.